New drug aims to stop weight loss in lung cancer patients during treatment
NCT ID NCT07150663
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced non-small cell lung cancer maintain their appetite and avoid significant weight loss while undergoing chemoradiotherapy. About 134 participants will receive either the drug or a placebo alongside standard treatment for up to 8 weeks. The goal is to improve quality of life during a tough treatment period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nanocrystalline megestrol acetate
What this could lead to
If it works, this could offer a way to help people with advanced lung cancer maintain their appetite and weight during intensive chemoradiotherapy.
What could go wrong
This is a phase 3 trial, but it focuses on symptom relief, not curing the cancer. The benefits may be modest, and side effects from the drug are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, TongjiMedical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••